Axogen vs SI-BONE
Axogen reported revenue of $225 million in fiscal 2025, about the same as SI-BONE's $201 million in fiscal 2025. Axogen's revenue grew 20.2% in its latest year, and SI-BONE's grew 20.2%. Axogen had an operating margin of -3.5%, against -11.1% at SI-BONE. Free cash flow was −$3 million at Axogen and −$9 million at SI-BONE.
Side by side
| Axogen | SI-BONE | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $225M | $201M |
| Revenue growth | 20.2% | 20.2% |
| Revenue growth a year, last 5 years | 14.9% | 22.3% |
| Gross margin | 74.3% | 79.6% |
| Operating margin | −3.5% | −11.1% |
| Net margin | −7.0% | −9.4% |
| Free cash flow | −$3M | −$9M |
| Free cash flow margin | −1.3% | −4.5% |
| Return on capital | −4.9% | −26.3% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.0% | 3.6% |
| Last close | $55.93 | $23.44 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $17.1 million | — |
| Piotroski F-score | 5 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AxogenSI-BONE
Operating margin
Percent of revenue
AxogenSI-BONE
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AxogenSI-BONE